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doi:10.1Objectives: Histidine-tryptophan-ketoglutarate (HTK–Custodiol) cardioplegic solution is administered as one
single dose for more than 2 hours of ischemia. No prospective randomized clinical study has compared the effects
of HTK and cold blood cardioplegia on myocardial damage in elective mitral valve surgery. Thus, the main aim of
the present study was to examine whether one single dose of cold antegrade HTK gives as good myocardial
protection as repetitive antegrade cold blood cardioplegia in mitral valve surgery.
Methods: Eighty consecutive patients undergoing elective isolated mitral valve surgery for mitral regurgitation,
with or without ablation for atrial fibrillation, were included in the study and randomized to HTK or blood
cardioplegia. Markers of myocardial injury (troponin-T and creatine kinase MB) were analyzed at baseline
and 7 hours, 1 day, 2 days, and 3 days after surgery.
Results: No significant difference in creatine kinase MB and troponin-T between HTK and blood cardioplegia
groups was found at any time point. There was a significant correlation between ischemic time and markers of
myocardial injury in the HTK group only and significantly more spontaneous ventricular fibrillation after release
of crossclamping in the HTK group.
Conclusions: One single dose of antegrade cold HTK cardioplegic solution in elective mitral valve surgery
protects the myocardium equally well as repetitive antegrade cold blood cardioplegia. (J Thorac Cardiovasc
Surg 2011;141:995-1001)Cardioplegia with histidine–tryptophan–ketoglutarate (HTK–
Custodiol; Koehler Chemi, Alsbach-Haenlien, Germany) or
Bretschneider solution for cardiac arrest during cardiac oper-
ations has been widely used clinically and reported in more
than 700,000 cases of open cardiac surgery.1-4 It is simple to
use, administered as one single dose, and it is claimed to
give sufficient myocardial protection for more than 2 hours
of cardiac arrest.5,6 In mitral valve surgery, the procedure
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Mcardioplegia. This problem might be circumvented by using
retrograde cardioplegia. However, retrograde cardioplegia
might be less feasible in minimally invasive approaches,
and insufficient delivery of cardioplegic solution to the right
ventricle has also been claimed.7 One single dose of antegrade
cardioplegia would thus be convenient in mitral valve surgery
compared with the repetitive doses normally given every 20 to
30 minutes when using antegrade blood or normal crystalloid
cardioplegia.
No prospective randomized studies comparing the effects
of HTK and cold blood cardioplegia on myocardial injury in
patients having mitral valve surgery have been reported.
This is surprising given the high number of procedures per-
formed with this cardioplegic solution. We8 have recently
shown that cold blood cardioplegia gives better protection
than cold crystalloid (modified St Thomas’ Hospital) cardi-
oplegia in aortic valve surgery. We therefore wanted to
compare the effect of cold HTK with that of the type of car-
dioplegia assumed to give the best myocardial protection,
namely, cold blood cardioplegia. Thus, the main aim of
the present study was to examine whether one single dose
of antegrade cold HTK in mitral valve surgery gives equally
good myocardial protection as repetitive antegrade cold
blood cardioplegia. A second aim was to examine whether
the single dose of HTK results in significantly shorter cross-
clamp times compared with repetitive blood cardioplegia.rdiovascular Surgery c Volume 141, Number 4 995
Abbreviations and Acronyms
CK ¼ creatine kinase
HTK ¼ histidine–tryptophan–ketoglutarate
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P
MFor this purpose a prospective randomized study was per-
formed using established markers of myocardial injury,
troponin-T and creatine kinase isoenzyme MB (CK-MB),
as end points.PATIENTS AND METHODS
Study Population and Design
Between March 2007 and December 2009, 80 consecutive patients
undergoing elective mitral valve surgery through a median sternotomy for
mitral regurgitation at Oslo University Hospital Ulleva˚l, Oslo, Norway,
and Sahlgrenska University Hospital, Gothenburg, Sweden, were included
in the study after informed written consent. The study protocol was ap-
proved by the local ethical committees. Eligible for operation were patients
with mitral regurgitation equal to or larger than grade 3 of 4. By opening of
sealed envelopes, patients were randomly allocated to 1 of 2 groups before
induction of anesthesia, receiving either repetitive antegrade cold (4C–
8C) blood cardioplegic solution or one single dose of antegrade cold
(4C–8C) HTK cardioplegic solution. No additional topical cooling was
used in any patient. The individual surgeon, if he believed it necessary,
was free to administer additional cardioplegic solution beyond that of the
protocol. In that case, however, the patient would be excluded from the
study. Four male patients were excluded from the study after randomization
(2 in each group) for the following reasons: One patient in the blood cardi-
oplegia group was excluded because of administration of additional cardio-
plegic solution before scheduled by the protocol (owing to emergence of
spontaneous heart rhythm after 10 minutes). Three patients, 1 in the blood
cardioplegia group and 2 patients in the HTK cardioplegia group, were
excluded because they received additional coronary artery bypass grafting
after randomization.
Because retrograde cardioplegia given through the coronary sinus cannot
always be achieved and might give inadequate protection of the right ven-
tricle unless combined with antegrade administration of cardioplegia
through the right coronary ostium,7 we decided to deliver the cardioplegic
solution antegradely only, in the present study. Warm induction and reper-
fusion cardioplegia were not used. Cold repetitive blood cardioplegia was
delivered antegradely through the ascending aorta strictly every 20 minutes
with a pressure of 300 mm Hg or less with a twin roller pump throughout the
period of aortic crossclamping. Initially, after crossclamping of the aorta,
a total of 900 mL of blood cardioplegic solution or 400 mL after asystole
was administered. Thereafter, 500 mL was administered antegradely every
20 minutes, assuring that the aortic valve was competent by digital palpation
of the pressure in the ascending aorta. In the group receiving HTK, approx-
imately 1800 mL of solution was infused antegradely in the aorta driven by
the hydrostatic pressure only (from approximately 2 m height) over a time
span of 6 to 8 minutes as recommended by the producer. If necessary, the
height of the container was adjusted to ensure that cardioplegic solution
was given over the recommended time span. Serum sodium levels were con-
trolled throughout the operation by repeated arterial blood gas samples and,
when necessary, additional sodium chloride was given to maintain serum
levels between 137 and 145 mmol/l.
Ablation for atrial fibrillation was the only concomitant procedure that was
allowed in addition to mitral valve surgery, and these patients were block-
randomized to ensure that the number of patients with ablation was equal
in the 2 cardioplegia groups. Patients with any other concomitant heart valve
disease or coronary artery stenoses (50%) were excluded from the study.996 The Journal of Thoracic and Cardiovascular SurgAnesthesia and Operative Technique
Before intubation, the patients were given benzodiazepine (diazepam or
flunitrazepam), fentanyl (3–5 mg/kg), thiopental (0.5–2.0 mg/kg), and cisa-
tracurium (0.15 mg/kg) or pancuronium bromide (0.1–0.15 mg/kg). The
anesthesia was continued with sevoflurane (1%–2% inspired). Under ex-
tracorporal circulation, the anesthesia was maintained with propofol (2–3
mg/kg per hour) or midazolam (0.02–0.04 mg/kg), fentanyl (1–2 mg/kg),
and sevoflurane (1%–2% inspired). Anticoagulation was performed with
systemic heparinization and supplemented as required to maintain an acti-
vated clotting time above 480 seconds. All operations were performed using
cardiopulmonary bypass with extracorporeal circulation using a roller
pump, ascending aortic cannulation, double venous cannulation, and mod-
erate systemic hypothermia (32C–34C).
Myocardial Protection
One of the following 2 cardioplegic solutions was used for myocardial
protection:
HTK solution. One liter of HTK solution (Custodiol; Koehler Chemi,
Alsbach-Haenlien, Germany) contains the following components: 15 mmol/
L sodium chloride, 9 mmol/L potassium chloride, 4 mmol/L magnesium
chloride, 18 mmol/L histidine hydrochloride, 180 mmol/L histidine,
2 mmol/L tryptophan, 30 mmol/L mannitol, 0.015 mmol/L calcium chlo-
ride, 1 mmol/L potassium hydrogen 2-ketoglutarate, osmolarity 310
mOsm/kg, pH 7.02–7.20. The cardioplegic solution was delivered at a tem-
perature of 4C–8C.
Blood cardioplegic solution. One liter of cold blood cardioplegic
solution, mixed at a ratio of 1:4 (cardioplegic solution/blood), contains the
following components: 179.1 mmol/L sodium, 22.2 mmol/L potassium,
18.6 mmol/L magnesium, 2.8 mmol/L calcium, 1.1 mmol/L procaine hydro-
cloride, 6.5 mmol/L acetate, 77.6 mmol/L chloride, 32.8 mmol/L hydrogen
carbonate, pH 7.30–7.40. Blood cardioplegic solution may have small
variations in individual variables. The cardioplegic solution was delivered
at a temperature of 4C–8C.
Use of Inotropic Support and Postarrest Recovery
Time
Inotropic support was administered after clinical judgment by the indi-
vidual anesthesiologist or cardiac surgeon mainly to keep mean arterial pres-
sure above 60 mm Hg. No rigid protocol was established regarding inotropic
support. The use of inotropic infusions longer than 20 minutes during the
first 24 postoperative hours and the time from release of aortic crossclamp
until weaning from extracorporeal circulation were registered.
Registration of Ventricular and Atrial Fibrillation
All patients were monitored with telemetry continuously throughout the
operation and the first 3 postoperative days. A 12-lead electrocardiogram
was recorded every day and compared with the electrocardiogram before
the operation. All patients in whom the heart started in ventricular fibrilla-
tion after removal of the crossclamp were registered. Ventricular fibrillation
was treated with 20 mmol potassium intravenously when serum potassium
was less than 5 mmol/L; otherwise, internal defibrillation applying up to
20 J was used. Patients with episodes of atrial fibrillation postoperatively,
without a history of atrial fibrillation preoperatively, were recorded.
Measurements of Cardiac Marker Proteins
Venous blood samples were collected before the operation and 7, 20, 44,
and 68 hours postoperatively. The time points were chosen owing to the
known profile of the enzyme release in plasma after myocardial ischemia.9
CK-MB and troponin-T were immediately analyzed as previously
described.10 Serum cardiac troponin-T concentration was measured by us-
ing electrochemiluminescence immunoassay on the Roche immunoassay
analyzer (Roche Diagnostics, Mannheim, Germany). The upper normalery c April 2011
Braathen et al Perioperative Managementreference limit (99th percentile) is less than 0.10 ng/mL. Serum CK-MB
concentration was measured by using electrochemiluminescence immuno-
assay on the Roche Elecsys 2010 immunoassay analyzer. The upper normal
reference limit (99th percentile) is less than 5 ng/mL.
Criteria for Perioperative Myocardial Infarction
Two of the following 3 criteria had to be fulfilled to diagnose a myocar-
dial infarction: (1) CK-MB of 100 mg/L or more and/or troponin-T of
3.0 mg/L or more, (2) appearance of a new postoperative Q wave on the elec-
trocardiogram of more than 0.03 second, and (3) a new hypokinetic or
akinetic area in the left or right ventricle by echocardiography.
Statistical Analysis
Data are presented as means  standard error of the mean. SigmaStat,
version 3.1 (Jandel Scientific GmbH, Erkrath, Germany), was used for
statistical analyses. In calculation of sample size, a 50% difference be-
tween groups regarding markers of myocardial damage was considered
significant. A 50% increase would still be well below the values consid-
ered as a peroperative myocardial infarction.8 On the basis of the results of
a previous study,11 a study with 80 patients would give a power of 0.97
with a P value of .05. Differences between 2 groups were analyzed by
the Student t test or the Mann–Whitney rank sum test for data normally
and not normally distributed, respectively. Analysis of variance for re-
peated measures was used to compare troponin-T and CK-MB levels
within and between the groups. Data not normally distributed were trans-
formed by natural logarithm to fit a normal distribution when examiningTABLE 1. Patient characteristics (mean ± SEM)
Characteristics
B
cardi
N
Age (y) 59
Females (no.) 13 (
Body weight (kg) 80
Body surface area (m2) 1.98
Mitral valve repair 33 (
Mitral valve replacement 5 (
AF ablation perop. 4 (
Ex.corp.circ. (min) 103
X-clamp (min) 73
Postarrest recovery (min) 21
Hemoglobin at max CK-MB (g/L) 11.0
Hemoglobin at max. troponin-T (g/L) 11.0
Creatinine preop. (mmol/L) 78
Creatinine 48 h postop. (mmol/L) 76
Postop. inotropic infusion>20 min (no.) 7 (
Postop. AF. (no.) 12 (
Thirty-day mortality (no.)
Myocardial infarction (no.)
Preop. EF  50 (no.) 36 (
Preop. use of beta-blockers (no.) 12 (
Postop. use of beta-blockers (no.) 20 (
Ventricular fibrillation after X-clamp removal (no.) 5 (
Internal defib. after X-clamp removal (no.) 3 (
Amounts of cardioplegic solution (mL) 1954
Postop red blood cell transfusion (no.) 8 (
Lowest core temp. under ex.corp.circ (C) 33.4
SEM, Standard error of the mean; HTK, histidine–tryptophan–ketoglutarate; AF, atrial fibrill
kinase isoenzyme MB; Perop, peroperatively; Postop, postoperatively; EF, ejection fractio
The Journal of Thoracic and Cathe relation between 2 continuous variables by linear regression. Compar-
isons of groups with dichotomous data were analyzed by Fisher’s exact
test or c2 as appropriate.RESULTS
Patient Characteristics
The characteristics of the patients are shown in Table 1.
There were more women in the group receiving blood
cardioplegia (34% vs 11%; P ¼ .03). There was no differ-
ence in crossclamp time between the blood cardioplegia
group and the HTK group (73  3 vs 75  3 minutes;
P ¼ .81). Furthermore, no significant differences in the
frequency of myocardial infarction, inotropic support, artial
fibrillation, or 30-day mortality were found between the 2
types of cardioplegia. There were no significant differences
in body weight and body surface area between the 2 groups
(Table 1).
After removal of the aortic crossclamp, there was a sig-
nificant difference between the 2 groups of patients regard-
ing spontaneous ventricular fibrillation. Twenty-seven
(71%) of 38 patients receiving HTK resumed cardiac activ-
ity after ischemia in ventricular fibrillation compared withlood
oplegia
HTK
cardioplegia P value
38 38
 2 59  2 .98
34%) 4 (11%) .03
 2 86  3 .10
 0.03 2.06  0.04 .12
87%) 34 (89%) 1
13%) 4 (11%) 1
11%) 6 (16%) .73
 3 107  4 .55
 3 75  3 .81
 1 20  1 .60
 0.2 11.5  0.2 .10
 0.2 11.4  0.2 .12
 3 81  2 .15
 5 75  3 .28
18%) 10 (27%) .54
32%) 8 (21%) .44
0 0
0 0
95%) 33 (87%) .43
32%) 11 (29%) 1
54%) 18 (49%) .82
13%) 27 (71%) <.001
8%) 12 (32%) .02
 65 1794  10 .05
21%) 5 (13%) .54
 0.2 33.5  0.2 .78
ation; Ex.corp.circ, extracorporeal circulation; X-clamp, crossclamp; CK-MB, creatine
n; Defib., defibrillation; no., number of patients; Temp., temperature.
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FIGURE 1. A, Maximum postoperative CK-MB with blood and HTK
cardioplegia (P ¼ .80). B, Maximum postoperative troponin-T with blood
and HTK cardioplegia (P ¼ .60). Values are mean  standard error of the
mean. CK-MB, Creatine kinase isoenzyme MB; HTK, histidine–trypto-
phan–ketoglutarate.
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FIGURE 2. A, Creatine kinase isoenzyme MB preoperatively and 7, 20,
44, and 68 hours postoperatively (P ¼ .65 between groups). B, Troponin-
T preoperatively and 7, 20, 44, and 68 hours postoperatively (P ¼ .30
between groups). Values are mean  standard error of the mean. CK-MB,
Creatine kinase isoenzyme MB; HTK, histidine–tryptophan–ketoglutarate;
Preop, preoperatively; PO, postoperatively.
Perioperative Management Braathen et al
P
M5 (13%) of 38 in the group receiving cold blood cardiople-
gia (P< .001).
CK-MB
Maximum CK-MB did not differ between the HTK group
and the blood cardioplegia group (56.2  4.7 vs 55.9 
4.9 mg/L; P ¼ .80; Figure 1, A). The highest value was mea-
sured 7 hours postoperatively (Figure 2, A). Furthermore,
there were no significant differences in CK-MB levels be-
tween groups at any postoperative time point (P ¼ .65, be-
tween groups). A significant correlation between ischemic
time and CK-MB was found in the HTK group (Figure 3,
C) but not in the blood cardioplegia group (Figure 3,A). There
was, however, no significant difference in the correlations
when compared between groups (P¼ .49). There was no sig-
nificant difference in maximum CK-MB levels between pa-
tients with or without postoperative ventricular fibrillation
after removal of the aortic crossclamp (P¼ .92), between pa-
tients with (n¼ 15) and without (n¼ 61) internal defibrillation
(P ¼ .47), or between men and women (P ¼ .20).998 The Journal of Thoracic and Cardiovascular SurgTroponin-T
Maximum troponin-T did not differ significantly be-
tween the HTK group and the blood cardioplegia group
(1.13  0.12 vs 1.05  0.11 mg/L; P ¼ .60; Figure 1, B).
In accordance with CK-MB, the highest troponin-T value
was found in the first blood sample 7 hours after the oper-
ation (Figure 2, B). There were no significant differences in
troponin-T levels between the groups at any postoperative
time point (P ¼ .30, between groups). A significant corre-
lation between time of ischemia and troponin-T was found
in the HTK group (Figure 3, D) whereas this correlation did
not reach the level of significance in the blood cardioplegia
group (Figure 3, B). Again, there was no significant differ-
ence in the correlations when compared between groups
(P ¼ .95). There was no significant difference in maximum
postoperative release of troponin-T between patients with
or without postoperative ventricular fibrillation after re-
moval of the aortic crossclamp (P ¼ .50), between patientsery c April 2011
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FIGURE 3. A and B, No correlation between cardiac enzymes and crossclamp time in the group of patients receiving cold blood cardioplegia. C and D,
Positive correlation between cardiac enzymes and crossclamp time in the group of patients receiving HTK cardioplegia. Dashed lines show 95% confidence
and prediction intervals. CK-MB, Creatine kinase isoenzyme MB; HTK, histidine–tryptophan–ketoglutarate.
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P
Mdefibrillated or not (P ¼ .93), or between men and women
(P ¼ .38).
DISCUSSION
This prospective, randomized study shows that one single
antegrade dose of cold HTK cardioplegia gives a cardiopro-
tective effect comparable with that of repeated doses ofThe Journal of Thoracic and Caantegrade cold blood cardioplegia in patients operated on
for elective mitral valve regurgitation when using CK-MB
and troponin-T as measures of myocardial injury. There
was a significant correlation between crossclamp time and
cardiac enzymes in the HTK group, but not in the group re-
ceiving blood cardioplegia. Crossclamp time was not signif-
icantly different between the 2 groups. Significantly higherrdiovascular Surgery c Volume 141, Number 4 999
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P
Mrates of ventricular fibrillation after removing the aortic
crossclamp were observed in the group of patients receiving
HTK, although this did not influence cardiac enzyme release.
HTK is an intracellular cardioplegic solution containing
low sodium concentration to arrest the heart by inhibiting
the rapid phase of the action potential, histidine as buffer,
ketoglutarate to improve the ATP energy production during
reperfusion, tryptophan to stabilize the cell membrane,
and mannitol to decrease the cellular edema.12-15 Because
of these qualities and the high buffer capacity, it has been
demonstrated that one single dose of HTK is sufficient for
myocardial protection up to more than 2 hours of
ischemia.6 The solution is also frequently used for organ
preservation in solid organ transplantation with longstanding
ischemia.16 Although HTK has been used for several years in
Germany under the name of Bretschneider solution, HTK
solution, or Custodiol,17 there are few studies comparing
the effect with other widely established types of cardioplegia.
In mitral valve surgery, the retractor normally used has to
be dismounted during administration of antegrade cardiople-
gia to ensure competence of the aortic valve and proper de-
livery to the coronary arteries. Retrograde cardioplegia
might be applied to circumvent this problem; however, it
cannot always be achieved as, for example, in minimally in-
vasive approaches. Moreover, insufficient delivery of cardi-
oplegic solution to the right ventricle has been claimed
unless supplemented with cardioplegic solution delivered
through the right coronary ostium.7 Thus, one single dose
of cardioplegic solution would be especially attractive in mi-
tral valve surgery compared with the repetitive doses nor-
mally given every 20 to 30 minutes when using blood and
normal crystalloid cardioplegia. This latter procedure might
interrupt mitral valve surgery several times per procedure.
Since blood cardioplegia is frequently used and believed
to give better myocardial protection than crystalloid cardio-
plegia,8 we compared the effect of HTK with that of blood
cardioplegia on myocardial injury. The average crossclamp
time in the present study was just above 70 minutes in both
groups. There was no difference in the release of the cardiac
enzymes CK-MB and troponin-T, although there was more
spontaneous ventricular fibrillation in the HTK group. Be-
cause of the relatively short crossclamp times in the present
study, there was no difference in crossclamp time between
groups, although one would expect a somewhat shorter
crossclamp time in favor of HTK in more complex and lon-
ger lasting procedures. The reason for this finding, although
HTK is only given as one single dose, is most likely that the
initial time of HTK administration is between 6 and 8 min-
utes and thus longer than for blood cardioplegia.
Although no differences in myocardial enzyme release
between HTK and blood cardioplegia could be demon-
strated in the present study, experimental studies comparing
multidose cold blood cardioplegia18 or multidose cold St
Thomas‘ Hospital solution12 with one single dose of cold1000 The Journal of Thoracic and Cardiovascular SurHTK have reported that HTK provides less adequate cardi-
oprotection. Both studies applied 60 minutes of crossclamp-
ing, which is comparable with our study, but they reported
almost double values of troponin-T in the groups receiving
HTK, and in the study by Aarsæther and coworkers,12 5 of
12 pigs could not be weaned from cardiopulmonary bypass.
In the study by Fanneløp and coworkers18 4 animals were
excluded owing to persistent therapy-resistant arrhythmias.
This was clearly not the result in patients, leading us to spec-
ulate that species differences and the known fragility of the
pig model might explain the differences between those
studies and the present. Taken together, although we did
not observe any differences in myocardial damage between
groups in the present study, further studies are needed to
document the safety of one dose of HTK in crossclamp times
exceeding those of the present study.
Clinically, surprisingly few prospective randomized stud-
ies have been performed with HTK solution as cardioprotec-
tion. Most studies have been performed on patients
undergoing coronary artery bypass grafting and only a rela-
tively small number of patients have been included. We have
not been able to find any prospective randomized studies
comparing multidose cold blood with single-dose HTK car-
dioplegia in mitral valve surgery. One retrospective study
with a total of 46 patients undergoing mitral valve replace-
ment with various additional procedures (bypass grafting,
maze, tricuspid valve surgery)19 reported in accordance
with the present study more spontaneous ventricular fibrilla-
tion after removal of the crossclamp in patients receiving
HTK. CK-MB and troponin-T were not measured and cross-
clamp time was 20 minutes longer in the HTK group. More-
over, the temperature of the cardioplegic solution given was
15C in blood compared twith 4C in the HTK solution,
making a comparison of the 2 cardioplegic solutions
difficult. In another small study20 reporting on 8 patients
receiving HTK cardioplegia only for minimally invasive
mitral valve surgery, it was concluded that HTK solution
provides safe long cardioplegic arrest time. Studies includ-
ing patients with other types of open cardiac operations
have reported various results.21,22
A significant increase in spontaneous ventricular fibrilla-
tion after crossclamp removal in the group of patients receiv-
ing HTK was demonstrated in the present study. An increase
in fibrillation after crossclamp removal has been linked to
conduction disturbances associated with inadequate intrao-
perative myocardial protection caused by heterogeneous re-
perfusion, oxidative stress, and alteration of electrolyte
concentration across the cell membranes and low adenosine
triphosphate levels.23-27 However, the most sensitive and
specific markers of myocardial injury in clinical use,
troponin-T and CK-MB, did not show any differences be-
tween groups in our study.
This study has some potential limitations. Although there
is a potential possibility of a type II statistical error,gery c April 2011
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Mstatistical calculations a priori should rule this out with
a 97% probability. There were more women in the blood
cardioplegia group. There was, however, no difference in
cardiac enzymes between men and women in the present
study and therefore this does not influence on our conclu-
sion. Ablation for atrial fibrillation was not an exclusion cri-
terion and may potentially influence troponin-T and CK-MB
levels. There was, however, no significant difference in the
number of patients receiving ablation in each group. Also,
mitral valve repair or replacement might play a potential
role regarding release of cardiac enzymes. These procedures
were also equally distributed between groups and should
therefore not influence the conclusion. The correlation be-
tween crossclamp time and cardiac enzymes in the HTK
group was significantly different, but there was no signifi-
cant difference when these correlations were compared
with the same correlations in the blood cardioplegia group.
Thus, the correlations in the HTK group should be
interpreted with caution because of the limited number of
observations.
In conclusion, one single dose of antegrade cold HTK car-
dioplegia in elective mitral valve surgery is as effective as re-
petitive antegrade cold blood cardioplegia in protecting the
myocardium, as measured by CK-MB and troponin-T. No
difference in crossclamp time was found. There was more
spontaneous ventricular fibrillation in the HTK group after
crossclamp removal, although the level of cardiac enzymes
was not different between groups. HTK cardioplegia is sim-
pler to use than blood cardioplegia in mitral valve surgery
because the operation can be performed continuously with-
out interruptions, for up to 2 hours of ischemia, provided no
coronary artery stenoses are present and moderate hypother-
mia of the patient is used.
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